Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06380907 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06380907 · ClinicalTrials.gov record · last posted 2026-08-10

A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque Psoriasis

StatusTerminated
PhasePhase 2
Started2024-05-22
View on ClinicalTrials.gov ↗
Why the trial stopped
Sponsor decision
from the ClinicalTrials.gov record
A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Dose-Ranging, Phase 2 Study to Evaluate the Efficacy and Safety of Different Doses of ZL-1102 Topical gel (A Human VH IL-17A Antibody Fragment) in the Treatment of Chronic Plaque Psoriasis

Protocol amendment history 5 changes detected by DataLookout

2026-08-11
Trial terminated
2026-08-11
Trial terminated: Sponsor decision
2026-08-11
Enrollment reduced: 250 → 65 participants
2026-08-11
Primary completion moved earlier: 2026-02-28 → 2025-12-16
2026-08-11
Completion moved earlier: 2026-03 → 2025-12-16
Trial Details
NCT Number NCT06380907
Lead Sponsor Zai Lab (Hong Kong), Ltd.
Collaborators: Zai Lab (US) LLC
Conditions Plaque Psoriasis
Enrollment 65 participants
Start Date 2024-05-22
Primary Completion 2025-12-16 (estimated)
Study Completion 2025-12-16 (estimated)
Updated on ClinicalTrials.gov 2026-08-10